Views & Analysis R&D round-up: Non-opioid painkiller space heats up As the MHRA announced that it would be convening an Expert Working
News Once-a-month HIV treatment sees promising phase III results Janssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III trials.
News ViiV redeems voucher for fast FDA review of HIV combination ViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine.
News GSK's blockbuster HIV drug linked with birth defects Regulators issue warning after preliminary study findings
News Stop obsessing about generic Advair, says GSK's Witty Growth elsewhere will soak up impact of US competitor, says Sir Andrew Witty.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
